Document Detail


Fish oil in the treatment of dyslipidemia.
MedLine Citation:
PMID:  18316953     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: The recent availability of a concentrated prescription omega-3 fatty acid preparation provides physicians with an additional anti-dyslipidemic agent at a time when limitations of statin therapy in dyslipidemic high-risk patients are recognized. This review examines the evidence supporting the use of omega-3 fatty acid treatment in dyslipidemic states. RECENT FINDINGS: There is now considerable evidence that omega-3 fatty acid treatment at the prescription strength of 4 g/day effectively and safely lowers triglyceride levels and increases low-density lipoprotein size, as well as affecting high-density lipoprotein metabolism. Similar effects have been noted in patients treated with statins, and add-on prescription omega-3 fatty acid therapy significantly increases the proportion of statin-treated dyslipidemic patients reaching their non-high-density lipoprotein cholesterol goals. In addition to past studies showing a cardioprotective effect of low-dose omega-3 fatty acid treatment against sudden death, a recent controlled clinical trial showed that 1.8 g of omega-3 fatty acid in statin-treated patients reduced major coronary events by 19% compared with statin plus placebo treatment. SUMMARY: Omega-3 fatty acid treatment should be considered in patients with severe hypertriglyceridemia as well as in high-risk patients with an atherogenic lipoprotein phenotype.
Authors:
Ronald B Goldberg; Anup K Sabharwal
Related Documents :
9555103 - Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apo...
16698313 - Docosahexaenoic acid enrichment can reduce l929 cell necrosis induced by tumor necrosis...
16656923 - Does ethylene mediate root growth inhibition by indole-3-acetic acid?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in endocrinology, diabetes, and obesity     Volume:  15     ISSN:  1752-2978     ISO Abbreviation:  -     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-04     Completed Date:  2008-04-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101308636     Medline TA:  Curr Opin Endocrinol Diabetes Obes     Country:  England    
Other Details:
Languages:  eng     Pagination:  167-74     Citation Subset:  IM    
Affiliation:
Division of Endocrinology and Metabolism, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. rgoldber@med.miami.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use
Atherosclerosis / prevention & control
Cardiovascular Diseases / complications,  drug therapy
Dyslipidemias / drug therapy*
Fatty Acids, Omega-3 / therapeutic use
Fish Oils / therapeutic use*
Humans
Lipoproteins / blood,  drug effects
Lipoproteins, VLDL / blood,  drug effects
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Fatty Acids, Omega-3; 0/Fish Oils; 0/Lipoproteins; 0/Lipoproteins, VLDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inpatient insulin therapy.
Next Document:  Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk ...